This study presents novel mechanistic evidence that chronic systemic treatment with an injected stabilized α-CGRP agonist is effective in the onset and ongoing AngII-induced hypertension and AAC-induced cardiac hypertrophy and heart failure in vivo. Here, AGT is linked to cardiac hypertrophy.